Spectrum Sees Potential Path For Poziotinib In NSCLC Despite Expected CRL

 
• By Alaric DeArment
  
The FDA sent a complete response letter to Spectrum for poziotinib in NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip